Anavasi Diagnostics

Anavasi Diagnostics is a Redmond, Washington-based medical technology company founded in 2020 that develops molecular point-of-care diagnostic solutions. The company’s primary offering is the AscencioDx platform, which includes a compact, rugged, and portable molecular detector paired with easy-to-use test kits. By leveraging sophisticated mechanical and bioengineering, the system is designed to provide highly accurate molecular diagnostic results in approximately 30 minutes, aiming to combine the precision typically found in centralized laboratory testing with the convenience required for point-of-care environments. Anavasi is a cGMP-compliant and ISO 13485-registered manufacturer, with its corporate headquarters and manufacturing facility featuring automated technology for high-volume production. The company was established by a team of science and engineering experts, including Barry Lutz, Bob Atkinson, and Minh Duong, to address the need for faster, more accessible, and cost-effective testing. By decentralizing diagnostic capabilities, Anavasi seeks to improve medical outcomes, particularly in the context of contagious diseases like COVID-19, by enabling healthcare professionals to obtain actionable diagnoses outside of traditional hospital settings. Their work has been supported by organizations such as the National Institutes of Health (NIH) through its RADx program, and the company continues to focus on bringing high-quality, efficient molecular testing to a broader market.